Viewing Study NCT05764395


Ignite Creation Date: 2025-12-24 @ 1:37 PM
Ignite Modification Date: 2025-12-30 @ 1:11 PM
Study NCT ID: NCT05764395
Status: SUSPENDED
Last Update Posted: 2024-10-10
First Post: 2023-02-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Sponsor: Vanderbilt-Ingram Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module